View Older Stories View More Recent Stories
-
Roth Capital Downgrades JA Solar Holdings Co., Ltd. (JASO) to Neutral
-
Wave Systems (WAVX) Announces Common, Warrants Offering
-
Wave Announces Public Offering
-
Ideal Power Inc. Announces Closing of Underwritten Public Offering of Common Stock
-
Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth Capital
-
Interactive Intelligence Has Priced $150 Million in Convertible Senior Notes
-
bluebird bio (BLUE) PT Raised to $192 at Roth Capital
-
Roth Affirms BioBlast Pharma (ORPN) at 'Buy' Following Q1 Report; U.S. Phase II/III HOPEMD Enrollment Remains Next Milestone
-
Roth Capital Downgrades Radiant Logistics (RLGT) to Neutral
-
Roth Capital Reiterates Buy on Green Plains (GPRE) Following Green Plains Partners (GPP) Public Prospectus Release
-
Canadian Solar (CSIQ) PT Raised to $46 at Roth Capital Despite Disappointing Investor Day
-
Roth Affirms Regeneron (REGN) at 'Neutral'; Dupilumab Success in Asthma Largely Priced-in
-
Streetinsider.com's Hot Lunchtime Reads 5/18: (AAPL) (FB) (PLT) (ANIP)
-
ANI Pharmaceuticals (ANIP) PT Lowered to $60 at Roth Capital
-
Roth Remains Positive on Concert Pharma (CNCE) Amid Upcoming AVP-786 Phase 3s (AVNR)
-
Pre-Open Stock Movers 05/18: (ANN) (ASNA) (SGYP) Higher; (EBIO) (TSLA) (ENDP) Lower (more...)
-
Roth Capital Reiterates Buy Following Pioneer Power (PPSI) Q1 Results
-
Roth Capital Starts Biodel (BIOD) at Buy, $5 PT
-
Roth Capital Previews bluebird bio (BLUE) Ahead of EHA Abstract
-
Roth Capital Sees Compelling Opportunities Ahead for uniQure BV (QURE)
-
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update
-
Ideal Power (IPWR) Prices 1.94M Common Offering at $7.75/Share
-
Ideal Power Inc. Prices Underwritten Public Offering of Common Stock
-
Ideal Power (IPWR) Announces Common Stock Offering
-
Ideal Power Inc. Announces Proposed Public Offering of Common Stock
-
Roth Capital Affirms Ligand Pharma (LGND) Following Positive SAGE-547 Update (SAGE)
-
Roth Capital Impressed by Trecora Resources (TREC) After Site Visit
-
Roth Capital Remain Bullish Leading up to Canadian Solar (CSIQ) Investor Day
-
Roth Capital 'Focus Pick' on TG Therapeutics (TGTX) Reiterated Amid ASCO Data
-
Argos Therapeutics (ARGS) Nearing Complete Enrollment in the Phase III ADAPT Study, Roth Capital Notes
-
Roth Capital Reiterated Bullish Stance on Aduro Biotech (ADRO) Following ASCO Abstracts
-
Roth Capital Raises Price Target Following Hackett Group's (HCKT) Q1 Results
-
Diamondback Energy (FANG) PT Raised at Roth Capital Despite EPS Miss
-
Roth Capital Reiterates Buy Following Clean Diesel Technologies (CDTI) Q1 Results
-
Roth Affirms Clean Diesel Tech (CDTI) at 'Buy'; HDD, Catalyst Performing Well
-
Roth Capital Remains Bullish Following Eco-stim Energy Solutions (ESES) Q1 Results
-
Roth Capital Remains Bullish Following Exar Corp. (EXAR) 4Q15 Results
-
Cytokinetics (CYTK) Clarifies Two Key Studies at R&D Event; Roth Affirms at 'Buy'
-
Roth Capital Says Consolidated Water Co (CWCO) Q1 Results Were 'Better than Meets the Eye'
-
NV5 Holdings (NVEE) Executing Well, Roth Capital Says; PT to $26
-
HII Technologies, Inc. Announces $3.05 Million Private Placement With Institutional and Accredited Investors
-
DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50
-
Roth Capital Sidelined on Plug Power (PLUG) Until Path Towards Profitability Clears
-
New Products, Growing Distributor Base Remain Key for Revolution Lighting (RVLT) - Roth Capital
-
Nuverra Environmental (NES) is Stabilizing Business as E&P Activity Ebbs; Roth Boosts PT to $4
-
Roth Capital Lowers PT on LivePerson (LPSN) Following the Loss of AT&T
-
Roth Capital lowers PT Despite Manitex Int'l's (MNTX) Revenue Beat
-
Roth Capital Reiterates Buy For Applied Genetic Technologies (AGTC) Following Q3
-
Rexahn (RNN) Valuation Remains Compelling at Supinoxin, RX-3117 Phase 1 Milestones Near - Roth Capital
-
Roth Remains Positive on Daqo New Energy (DQ); Poly ASPs Can Remain at Current Levels for Only so Long

